Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 1, 2003, Pages 60-67

  Ducobu, Jean ^a,d   VanHaelst, Luc ^b   Salomon, Herve ^c  

^a Centre Hospitalier Universitaire de Tivoli   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c Laboratoires Fournier   (France)

^d ACUMED   (United Kingdom)

Author keywords

Cholesterol; Dyslipidemia; Fenofibrate therapy; Hypercholesterolemia; Statin therapy

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CHOLESTEROL; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PRAVASTATIN; PROCETOFEN; TREATMENT OUTCOME;

EID: 0037216556     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200301000-00008     Document Type: Article

References (25)

1. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93.
2. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
3. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000;2:208-17.
4. Stalenhoef AF, Stehouwer CD. Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant. Ned Tijdschr Geneeskd 2000;144:822-3.
5. Munoz A, Guichard JP, Reginault P. Micronised fenofibrate. Atherosclerosis 1994;110(suppl):S45-8.
6. Adkins JC, Faulds D. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997;54:615-33.
7. Haria M, McTavish D. Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997; 53:299-336.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
10. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335:1001-9.
11. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
13. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: The Framingham Heart Study. Can J Cardiol 1988;4(suppl A):5A-10A.
14. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989;79:8-15.
15. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
16. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
17. Gotto A. Primary prevention of coronary heart disease: Where do we go from here? Arch Intern Med 2001;161:922-4.
18. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 1992;85:37-45.
19. Brown VW, Dujovne CA, Farquhar JW, et al. Effects of fenofibrate on plasma lipids: Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 1986;6:670-8.
20. Siedel J, Hagele EO, Ziegenhorn J, et al. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983;29:1075-80.
21. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476-82.
22. Rosseneu M, Vercaemst R, Steinberg KK, et al. Some considerations of methodology and standardization of apolipoprotein B immunoassays. Clin Chem 1983;29:427-33.
23. Lopes-Virella MF, Stone P, Ellis S, et al. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977;23:882-4.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1072;18:499-502.
25. Labeur C, Shepherd J, Rosseneu M. Immunological assays of apolipoproteins in plasma: Methods and instrumentation. Clin Chem 1990;36:591-7.